In patients with acquired hypothalamic obesity, setmelanotide reduced BMI at 52 weeks compared with placebo, according to results of the TRANSCEND trial presented at ENDO 2025. For the phase 3 trial, ...

Many women in their 20s and 30s are experiencing thyroid-related symptoms, often linked to chronic stress disrupting the ...